[1] Mebazaa A., Pitsis A.A., Rudiger A., Toller W., Longrois D., Ricksten S.E., Bobek I., De Hert S., Wieselthaler G., Schirmer U., von Segesser L.K., Sander M., Poldermans D., Ranucci M., Karpati P.C., Wouters P., Seeberger M., Schmid E.R., Weder W., Follath F. Clinical review: Practical recommendations on the management of perioperative heart failure in cardiac surgery. Critical Care, 2010, vol. 14, № 2, pp. 201–215.
[2] Nashef S.A., Roques F., Sharples L.D., Nilsson J., Smith C., Goldstone A.R., Lockowandt U. EuroSCORE II. Eur J Cardiothorac Surg, 2012, vol. 41, № 4, pp. 734–744.
[3] Lenz M., Krychtiuk K.A., Goliasch G., Distelmaier K., Wojta J., Heinz G., Speidl W.S. N-terminal pro-brain natriuretic peptide and high sensitivity troponin T exhibit additive prognostic value for the outcome of critically ill. Eur Heart J Acute Cardiovasc Care, 2018, Apr 1:2048872618768088. doi: 10.1177/2048872618768088.
[4] Braunwald E. Heart failure. JACC: Heart Fail, 2013, vol. 1, № 1, pp. 1–20. doi:10.1016/j.jchf.2012.10.002.
[5] Taub P.R., Daniels L.B., Maisel L.S Usefulness of B-type natriuretic peptide levels in predicting hemodynamic and clinical decompensation. Heart Fail Clin. 2009, vol. 5, № 2, pp. 169–175. doi: 10.1016/j.hfc.2008.11.009.
[6] Januzzi J.L.Jr., Rehman S.U., Mohammed A.A., Bhardwaj A., Barajas L., Barajas J., Kim H.N., Baggish A.L., Weiner R.B., Chen-Tournoux A., Marshall J.E., Moore S.A., Carlson W.D., Lewis G.D., Shin J., Sullivan D., Parks K., Wang T.J., Gregory S.A., Uthamalingam S., Semigran M.J. Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J Am Coll Cardiol, 2011, vol. 58, № 18, pp. 1881–1889.
[7] Ponikowski P., Voors A.A., Anker S.D., Bueno H., Cleland J.G.F., Coats A.J.S., Falk V., Gonz lez-Juanatey J.R., Harjola V.P., Jankowska E.A., Jessup M., Linde C., Nihoyannopoulos P., Parissis J.T., Pieske B., Riley J.P., Rosano G.M.C., Ruilope L.M., Ruschitzka F., Rutten F.H., van der Meer P. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart. Eur Heart J, 2016, vol. 37, № 27, pp. 2129–2200.
[8] Maisel A., Mueller C., Adams K.Jr., Anker S.D., Aspromonte N., Cleland J.G., Cohen-Solal A., Dahlstrom U., DeMaria A., Di Somma S., Filippatos G.S., Fonarow G.C., Jourdain P., Komajda M., Liu P.P., McDonagh T., McDonald K., Mebazaa A., Nieminen M.S., Peacock W.F., Tubaro M., Valle R., Vander-hyden M., Yancy C.W., Zannad F., Braunwald E. State of the art: Using natriuretic peptide levels in clinical practice. Eur J Heart Fail, 2008, vol. 10, № 9, pp. 824–839.
[9] Karthikeyan G., Moncur R.A., Levine O., Heels-Ansdell D., Chan M.T., Alonso-Coello P., Yusuf S., Sessler D., Villar J.C., Berwanger O., McQueen M.,Mathew A., Hill S., Gibson S., Berry C., Yeh H.M., Devereaux P.J. Is a pre-operative brain natriuretic peptide or N-terminal pro-B-type natriuretic peptide measurement an independent predictor of adverse cardiovascular outcomes within 30 days of noncardiac surgery? A systematic review and meta-analysis of observational studies. J Am Coll Cardiol, 2009, vol. 54, № 17, pp. 1599–1606.
[10] Rodseth R.N., Biccard B.M., Le Manach Y., Sessler D.I., Lurati Buse G.A., Thabane L., Schutt R.C., Bolliger D., Cagini L., Cardinale D., Chong C.P., Chu R., Cnotliwy M., Di Somma S., Fahrner R., Lim W.K., Mahla E., Manikandan R., Puma F., Pyun W.B., Radovi M., Rajagopalan S., Suttie S., Vanniyasingam T., van Gaal W.J., Waliszek M., Devereaux P.J. The prognostic value of pre-operative and post-operative B-type natriuretic peptides in patients undergoing noncardiac surgery: B-type natriuretic peptide and N-terminal fragment of pro-B-type natriuretic peptide: a systematic review and individual patient data meta-analysis. J Am Coll Cardiol, 2014, vol. 63, № 2, pp.170–180.
[11] Polineni S., Parker D.M., Alam S.S., Thiessen-Philbrook H., McArthur E., DiScipio A.W., Malenka D.J., Parikh C.R, Garg A.X., Brown J.R. Predictive Ability of Novel Cardiac Biomarkers ST2, Galectin-3, and NT-ProBNP Before Cardiac Surgery. J Am Heart Assoc, 2018, vol. 7, № 4, pii: e008371. doi: 10.1161/JAHA.117.008371.
[12] Thygesen K., Alpert J.S., Jaffe A.S., Chaitman B.R., Bax J.J., Morrow D.A., White H.D. Fourth universal definition of myocardial infarction. Eur Heart J, 2018, Aug 25. doi: 10.1093/eurheartj/ehy462.
[13] Baron J.M., Lewandrowski E.L., Januzzi J.L., Bajwa E.K., Thompson B.T., Lewandrowski K.B. Measurement of high-sensitivity troponin T in noncardiac medical intensive care unit patients. Correlation to mortality and length of stay. Am J Clin Pathol, 2014, vol. 141, № 4, pp. 488–493.
[14]] Brown J.R., Jacobs J.P., Alam S.S., Thiessen Philbrook H., Everett A., Likosky D.S., Lobdell K., Wyler von Ballmoos M.C., Parker D.M., Garg A.X., Mackenzie T., Jacobs M.L., Parikh C.R. Utility of Biomarkers to Improve Prediction of Readmission or Mortality After Cardiac Surgery. Ann Thorac Surg, 2018, Aug 4, pii: S0003 4975(18)31058 0. doi: 10.1016/ j.athoracsur.2018.06.052.
[15] Shen J.T., Xu M., Wu Y., Wen S.H., Li X., Zhao B.C., Huang W.Q. Association of pre-operative troponin levels with major adverse cardiac events and mortality after noncardiac surgery: A systematic review and meta-analysis. Eur J Anaesthesiol, 2018, vol. 35, № 11, pp. 815–824.
[16] Norusis M. SPSS 13.0 Guide to Data Analysis. Upper Saddle River, N.J.: Prentice Hall, Inc, 2004, pp. 134.
[17] Glantz S.A. Primer of Biostatistics. New York [etc]: McGrawHill Medical, 1994. (Russ. ed.: Danilov Yu.A., Buzikashvili N.E., Samoylov D.V. Medikobiologicheskaya statistika. Moscow: Praktika , 1999. 119 p.).